- Home
- BRTX vs TLPH Comparison
BRTX vs TLPH Comparison
Compare BRTX & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- TLPH
- Stock Information
- Founded
- BRTX 1997
- TLPH 2005
- Country
- BRTX United States
- TLPH United States
- Employees
- BRTX N/A
- TLPH N/A
- Industry
- BRTX Managed Health Care
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- BRTX Health Care
- TLPH Health Care
- Exchange
- BRTX Nasdaq
- TLPH Nasdaq
- Market Cap
- BRTX 12.5M
- TLPH 10.6M
- IPO Year
- BRTX N/A
- TLPH 2011
- Fundamental
- Price
- BRTX $1.62
- TLPH $0.42
- Analyst Decision
- BRTX Strong Buy
- TLPH Strong Buy
- Analyst Count
- BRTX 1
- TLPH 1
- Target Price
- BRTX $18.00
- TLPH $6.00
- AVG Volume (30 Days)
- BRTX 89.7K
- TLPH 919.9K
- Earning Date
- BRTX 08-12-2025
- TLPH 08-13-2025
- Dividend Yield
- BRTX N/A
- TLPH N/A
- EPS Growth
- BRTX N/A
- TLPH N/A
- EPS
- BRTX N/A
- TLPH N/A
- Revenue
- BRTX $391,000.00
- TLPH $27,000.00
- Revenue This Year
- BRTX $216.71
- TLPH N/A
- Revenue Next Year
- BRTX $60.63
- TLPH $14,533.26
- P/E Ratio
- BRTX N/A
- TLPH N/A
- Revenue Growth
- BRTX 161.54
- TLPH N/A
- 52 Week Low
- BRTX $1.21
- TLPH $0.38
- 52 Week High
- BRTX $2.55
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- BRTX 48.45
- TLPH 42.40
- Support Level
- BRTX $1.43
- TLPH $0.38
- Resistance Level
- BRTX $1.75
- TLPH $0.79
- Average True Range (ATR)
- BRTX 0.12
- TLPH 0.06
- MACD
- BRTX 0.01
- TLPH -0.00
- Stochastic Oscillator
- BRTX 52.78
- TLPH 10.51
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.